Skip to main content
SpringerLink
Log in

In Vitro Neutralization Assay Using Cultured Hepatitis C Virus

  • Protocol
  • First Online:
Hepatitis C Virus Protocols

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1911))

Abstract

The method outlined here enables evaluation of the neutralization potency of monoclonal and polyclonal antibodies against in vitro cultured hepatitis C virus (HCV). The high variation in envelope protein sequence among HCV isolates necessitates the inclusion of several isolates, spanning the major genotypes of HCV, in order to make strong conclusions concerning the cross-reactive neutralization potential of a given antibody. This would be particularly relevant for any neutralization experiments aimed at uncovering novel therapeutic- or vaccine-relevant antibodies. In addition, these assays can also be used to compare neutralization sensitivity of novel cultured HCV to that of previously characterized isolates.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC et al (2005) Complete replication of hepatitis C virus in cell culture. Science 309:623–626

    Article  CAS  Google Scholar 

  2. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z et al (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791–796

    Article  CAS  Google Scholar 

  3. Gottwein JM, Scheel TK, Hoegh AM, Lademann JB, Eugen-Olsen J, Lisby G et al (2007) Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology 133:1614–1626

    Article  CAS  Google Scholar 

  4. Jensen TB, Gottwein JM, Scheel TK, Hoegh AM, Eugen-Olsen J, Bukh J (2008) Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection. J Infect Dis 198:1756–1765

    Article  Google Scholar 

  5. Scheel TK, Gottwein JM, Jensen TB, Prentoe JC, Hoegh AM, Alter HJ et al (2008) Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc Natl Acad Sci U S A 105:997–1002

    Article  CAS  Google Scholar 

  6. Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML et al (2009) Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49:364–377

    Article  CAS  Google Scholar 

  7. Carlsen TH, Pedersen J, Prentoe JC, Giang E, Keck ZY, Mikkelsen LS et al (2014) Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a. Hepatology 60:1551–1562

    Article  CAS  Google Scholar 

  8. Scheel TK, Gottwein JM, Carlsen TH, Li YP, Jensen TB, Spengler U et al (2011) Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations. J Virol 85:2891–2906

    Article  CAS  Google Scholar 

  9. Pedersen J, Carlsen TH, Prentoe J, Ramirez S, Jensen TB, Forns X et al (2013) Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies. Hepatology 58:1587–1597

    Article  CAS  Google Scholar 

  10. Prentoe J, Verhoye L, Velazquez Moctezuma R, Buysschaert C, Farhoudi A, Wang R et al (2016) HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice. Gut 65:1988–1997

    Article  CAS  Google Scholar 

  11. Sabo MC, Luca VC, Prentoe J, Hopcraft SE, Blight KJ, Yi M et al (2011) Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J Virol 85:7005–7019

    Article  CAS  Google Scholar 

  12. Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J et al (2012) Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A 109:6205–6210

    Article  CAS  Google Scholar 

  13. Keck ZY, Xia J, Wang Y, Wang W, Krey T, Prentoe J et al (2012) Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog 8:e1002653

    Article  CAS  Google Scholar 

  14. Keck Z, Wang W, Wang Y, Lau P, Carlsen TH, Prentoe J et al (2013) Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J Virol 87:37–51

    Article  CAS  Google Scholar 

  15. Prentoe J, Jensen TB, Meuleman P, Serre SB, Scheel TK, Leroux-Roels G et al (2011) Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J Virol 85:2224–2234

    Article  CAS  Google Scholar 

  16. Prentoe J, Velazquez-Moctezuma R, Foung SK, Law M, Bukh J (2016) Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity. Hepatology 64:1881–1892

    Article  CAS  Google Scholar 

  17. Gottwein JM, Jensen TB, Mathiesen CK, Meuleman P, Serre SB, Lademann JB et al (2011) Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A. J Virol 85:8913–8928

    Article  CAS  Google Scholar 

  18. Gottwein JM, Scheel TK, Callendret B, Li YP, Eccleston HB, Engle RE et al (2010) Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol 84:5277–5293

    Article  CAS  Google Scholar 

  19. Prentoe J, Bukh J (2011) Hepatitis C virus expressing flag-tagged envelope protein 2 has unaltered infectivity and density, is specifically neutralized by flag antibodies and can be purified by affinity chromatography. Virology 409:148–155

    Article  CAS  Google Scholar 

  20. Blight KJ, Kolykhalov AA, Rice CM (2000) Efficient initiation of HCV RNA replication in cell culture. Science 290:1972–1974

    Article  CAS  Google Scholar 

  21. Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, Balfe P et al (2008) Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol 82:12020–12029

    Article  CAS  Google Scholar 

  22. Bailey JR, Wasilewski LN, Snider AE, El-Diwany R, Osburn WO, Keck Z et al (2015) Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. J Clin Invest 125:437–447

    Article  Google Scholar 

  23. Pedersen J, Jensen TB, Carlsen TH, Schonning K, Christensen PB, Laursen AL et al (2013) Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome. PLoS One 8:e62674

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Hvidovre Hospital, Hvidovre, Denmark

    Jannick Prentoe & Jens Bukh

  2. Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

    Jannick Prentoe & Jens Bukh

Authors
  1. Jannick Prentoe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jens Bukh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jens Bukh .

Editor information

Editors and Affiliations

  1. Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA

    Mansun Law

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Prentoe, J., Bukh, J. (2019). In Vitro Neutralization Assay Using Cultured Hepatitis C Virus. In: Law, M. (eds) Hepatitis C Virus Protocols . Methods in Molecular Biology, vol 1911. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8976-8_29

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-8976-8_29

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-8975-1

  • Online ISBN: 978-1-4939-8976-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation